GlobeNewsWire
30 Mar 2026, 13:00 UTC · 24w ago
Verdict
Headline takes no side. We score TPST +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Tempest reported positive interim data from the REDEEM-1 Phase 1/2a trial of TPST-2003 for relapsed/refractory multiple myeloma.
So whatPositive clinical trial data for a lead asset is the primary driver of valuation for clinical-stage biotech companies.
More positive than 98% of claims this week
The company plans to potentially initiate a U.S. registrational study for TPST-2003 later in 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
Tempest completed the strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.
More positive than 77% of claims this week
Matt Angel, Ph.D., has been named the new Chief Executive Officer and President.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive interim data for its lead CAR-T program and completed a strategic acquisition to strengthen its pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
57m ago
−56.3%
Price is moving against the score
$0.7554 vs $1.73 close before publication (Mar 27) · not market-adjusted
TPST chart →
